Raludotatug deruxtecan (R-DXd) received FDA breakthrough therapy designation for CDH6-expressing platinum-resistant ovarian, primary peritoneal, or fallopian tube cancers. Phase 1 study demonstrated a ...

The popular harem action series High School DxD is getting a new spinoff manga series based on the descendant of Miyamoto Musashi -- its first in over 10 years. High School DxD's official anime ...

The TROPION-Breast02 trial is the first to show overall survival benefit in this patient population, indicating a potential ...

New analysis of the DESTINY-Breast06 trial demonstrated that trastuzumab deruxtecan (T-DXd) provides meaningful clinical benefit regardless of time to progression on prior endocrine therapy, offering ...

Dato-DXd lengthened the average time it took patients with HR-positive, HER2-low or -negative metastatic breast cancer to experience disease progression, study results showed. Patients with hormone ...

High school and anime are like two peas in a pod — so it was no surprise to see High School DxD take off. Based on the light novel series of the same name by Ichiei Ishibumi, this supernatural comedy ...

At the recent American Society of Clinical Oncology (ASCO) annual meeting, interim results from the DESTINY-Breast09 trial highlighted a potential shift in frontline treatment for metastatic ...

The FDA has granted priority review to the supplemental biologics license application (sBLA) of fam-trastuzumab ...

Patient undergoing chemotherapy. Trastuzumab deruxtecan improves overall survival vs trastuzumab emtansine in previously treated, HER2-positive, advanced breast cancer, a phase 3 trial suggests.

Patients with advanced squamous or nonsquamous NSCLC without a common EGFR-activating mutation whose disease had progressed on previous therapies including platinum-based chemotherapy, immune ...